Vancouver Declaration II on Global Headache Patient Advocacy 2019

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Vancouver Declaration II on Global Headache Patient Advocacy 2019. / Dodick, David W; Ashina, Messoud; Sakai, Fumihiko; Grisold, Wolfgang; Miyake, Hitoshi; Henscheid-Lorenz, Deborah; Craven, Audrey; Ruiz de la Torre, Elena; Koh, Rachel; Reznik, Nikita; Bance, Lisa; Leroux, Elizabeth; Edvinsson, Lars; International Headache Society Global Patient Advocacy Coalition.

I: Cephalalgia : an international journal of headache, Bind 40, Nr. 10, 09.2020, s. 1017-1025.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Dodick, DW, Ashina, M, Sakai, F, Grisold, W, Miyake, H, Henscheid-Lorenz, D, Craven, A, Ruiz de la Torre, E, Koh, R, Reznik, N, Bance, L, Leroux, E, Edvinsson, L & International Headache Society Global Patient Advocacy Coalition 2020, 'Vancouver Declaration II on Global Headache Patient Advocacy 2019', Cephalalgia : an international journal of headache, bind 40, nr. 10, s. 1017-1025. https://doi.org/10.1177/0333102420921162

APA

Dodick, D. W., Ashina, M., Sakai, F., Grisold, W., Miyake, H., Henscheid-Lorenz, D., Craven, A., Ruiz de la Torre, E., Koh, R., Reznik, N., Bance, L., Leroux, E., Edvinsson, L., & International Headache Society Global Patient Advocacy Coalition (2020). Vancouver Declaration II on Global Headache Patient Advocacy 2019. Cephalalgia : an international journal of headache, 40(10), 1017-1025. https://doi.org/10.1177/0333102420921162

Vancouver

Dodick DW, Ashina M, Sakai F, Grisold W, Miyake H, Henscheid-Lorenz D o.a. Vancouver Declaration II on Global Headache Patient Advocacy 2019. Cephalalgia : an international journal of headache. 2020 sep.;40(10):1017-1025. https://doi.org/10.1177/0333102420921162

Author

Dodick, David W ; Ashina, Messoud ; Sakai, Fumihiko ; Grisold, Wolfgang ; Miyake, Hitoshi ; Henscheid-Lorenz, Deborah ; Craven, Audrey ; Ruiz de la Torre, Elena ; Koh, Rachel ; Reznik, Nikita ; Bance, Lisa ; Leroux, Elizabeth ; Edvinsson, Lars ; International Headache Society Global Patient Advocacy Coalition. / Vancouver Declaration II on Global Headache Patient Advocacy 2019. I: Cephalalgia : an international journal of headache. 2020 ; Bind 40, Nr. 10. s. 1017-1025.

Bibtex

@article{77a63fbd600a466ca0da2c33eb55ebb9,
title = "Vancouver Declaration II on Global Headache Patient Advocacy 2019",
abstract = "In 2017, the International Headache Society convened a Global Patient Advocacy Summit (GPAS-1) to begin a collaborative effort involving patients, patient advocates, patient advocacy organizations, healthcare professionals, scientists, professional pain, neurology, and headache societies, pharmaceutical manufacturers, and regulatory agencies to advance issues of importance to patients affected by headache worldwide. In September 2019, the second Global Patient Advocacy Summit (GPAS-2) was convened to revisit issues from the inaugural meeting, assess the progress of the International Headache Society Global Patient Advocacy Coalition (IHS-GPAC) in meeting the goals set forth therein, and discuss strategies for achieving established goals and supporting future development. Short- and long-term mandates from the first Summit were realized, including publishing the Vancouver Declaration on Global Headache Patient Advocacy 2018, determining the governing and operational structures of the IHS-GPAC, and helping to facilitate the first World Federation of Neurology World Brain Day dedicated to migraine. Another short-term mandate, creating a unified advocacy strategy, was fulfilled by the Coalition's decision to focus on encouraging support from employers and implementing employee support programs for people with migraine. To help execute the strategy, the Coalition is developing an employer engagement toolkit that will educate employers and employees about the impact of migraine in the workplace, reduce stigma directed toward employees with migraine, and facilitate the care of employees with migraine to reduce the burden of illness and improve workplace productivity. Coalition members will disseminate the toolkit and encourage the adoption of migraine workplace programs by employers worldwide. The Coalition has established an alliance with two global, multinational employers to expand migraine awareness and support among policy makers and other stakeholders around the world. The IHS-GPAC met many of the goals established at GPAS-1, and it has initiated a global strategy focused on the psychosocial and economic toll of headache disorders, especially migraine, in the workplace. Ongoing and future activities will explore a range of opportunities with employers and across the full spectrum of advocacy goals.",
author = "Dodick, {David W} and Messoud Ashina and Fumihiko Sakai and Wolfgang Grisold and Hitoshi Miyake and Deborah Henscheid-Lorenz and Audrey Craven and {Ruiz de la Torre}, Elena and Rachel Koh and Nikita Reznik and Lisa Bance and Elizabeth Leroux and Lars Edvinsson and {International Headache Society Global Patient Advocacy Coalition}",
year = "2020",
month = sep,
doi = "10.1177/0333102420921162",
language = "English",
volume = "40",
pages = "1017--1025",
journal = "Cephalalgia",
issn = "0800-1952",
publisher = "SAGE Publications",
number = "10",

}

RIS

TY - JOUR

T1 - Vancouver Declaration II on Global Headache Patient Advocacy 2019

AU - Dodick, David W

AU - Ashina, Messoud

AU - Sakai, Fumihiko

AU - Grisold, Wolfgang

AU - Miyake, Hitoshi

AU - Henscheid-Lorenz, Deborah

AU - Craven, Audrey

AU - Ruiz de la Torre, Elena

AU - Koh, Rachel

AU - Reznik, Nikita

AU - Bance, Lisa

AU - Leroux, Elizabeth

AU - Edvinsson, Lars

AU - International Headache Society Global Patient Advocacy Coalition

PY - 2020/9

Y1 - 2020/9

N2 - In 2017, the International Headache Society convened a Global Patient Advocacy Summit (GPAS-1) to begin a collaborative effort involving patients, patient advocates, patient advocacy organizations, healthcare professionals, scientists, professional pain, neurology, and headache societies, pharmaceutical manufacturers, and regulatory agencies to advance issues of importance to patients affected by headache worldwide. In September 2019, the second Global Patient Advocacy Summit (GPAS-2) was convened to revisit issues from the inaugural meeting, assess the progress of the International Headache Society Global Patient Advocacy Coalition (IHS-GPAC) in meeting the goals set forth therein, and discuss strategies for achieving established goals and supporting future development. Short- and long-term mandates from the first Summit were realized, including publishing the Vancouver Declaration on Global Headache Patient Advocacy 2018, determining the governing and operational structures of the IHS-GPAC, and helping to facilitate the first World Federation of Neurology World Brain Day dedicated to migraine. Another short-term mandate, creating a unified advocacy strategy, was fulfilled by the Coalition's decision to focus on encouraging support from employers and implementing employee support programs for people with migraine. To help execute the strategy, the Coalition is developing an employer engagement toolkit that will educate employers and employees about the impact of migraine in the workplace, reduce stigma directed toward employees with migraine, and facilitate the care of employees with migraine to reduce the burden of illness and improve workplace productivity. Coalition members will disseminate the toolkit and encourage the adoption of migraine workplace programs by employers worldwide. The Coalition has established an alliance with two global, multinational employers to expand migraine awareness and support among policy makers and other stakeholders around the world. The IHS-GPAC met many of the goals established at GPAS-1, and it has initiated a global strategy focused on the psychosocial and economic toll of headache disorders, especially migraine, in the workplace. Ongoing and future activities will explore a range of opportunities with employers and across the full spectrum of advocacy goals.

AB - In 2017, the International Headache Society convened a Global Patient Advocacy Summit (GPAS-1) to begin a collaborative effort involving patients, patient advocates, patient advocacy organizations, healthcare professionals, scientists, professional pain, neurology, and headache societies, pharmaceutical manufacturers, and regulatory agencies to advance issues of importance to patients affected by headache worldwide. In September 2019, the second Global Patient Advocacy Summit (GPAS-2) was convened to revisit issues from the inaugural meeting, assess the progress of the International Headache Society Global Patient Advocacy Coalition (IHS-GPAC) in meeting the goals set forth therein, and discuss strategies for achieving established goals and supporting future development. Short- and long-term mandates from the first Summit were realized, including publishing the Vancouver Declaration on Global Headache Patient Advocacy 2018, determining the governing and operational structures of the IHS-GPAC, and helping to facilitate the first World Federation of Neurology World Brain Day dedicated to migraine. Another short-term mandate, creating a unified advocacy strategy, was fulfilled by the Coalition's decision to focus on encouraging support from employers and implementing employee support programs for people with migraine. To help execute the strategy, the Coalition is developing an employer engagement toolkit that will educate employers and employees about the impact of migraine in the workplace, reduce stigma directed toward employees with migraine, and facilitate the care of employees with migraine to reduce the burden of illness and improve workplace productivity. Coalition members will disseminate the toolkit and encourage the adoption of migraine workplace programs by employers worldwide. The Coalition has established an alliance with two global, multinational employers to expand migraine awareness and support among policy makers and other stakeholders around the world. The IHS-GPAC met many of the goals established at GPAS-1, and it has initiated a global strategy focused on the psychosocial and economic toll of headache disorders, especially migraine, in the workplace. Ongoing and future activities will explore a range of opportunities with employers and across the full spectrum of advocacy goals.

U2 - 10.1177/0333102420921162

DO - 10.1177/0333102420921162

M3 - Journal article

C2 - 32345038

VL - 40

SP - 1017

EP - 1025

JO - Cephalalgia

JF - Cephalalgia

SN - 0800-1952

IS - 10

ER -

ID: 251795656